

Zachary T Bloomgarden

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9030981/publications.pdf>

Version: 2024-02-01

198
papers

3,973
citations

159585

30
h-index

149698

56
g-index

231
all docs

231
docs citations

231
times ranked

5145
citing authors

#	ARTICLE	IF	CITATIONS
1	American Association of Clinical Endocrinologists and American College of Endocrinology "Clinical Practice Guidelines for Developing A Diabetes Mellitus Comprehensive Care Plan " 2015 " Executive Summary. Endocrine Practice, 2015, 21, 413-437.	2.1	359
2	Lower Baseline Glycemia Reduces Apparent Oral Agent Glucose-Lowering Efficacy: A meta-regression analysis. Diabetes Care, 2006, 29, 2137-2139.	8.6	204
3	Type 2 Diabetes in the Young: The evolving epidemic. Diabetes Care, 2004, 27, 998-1010.	8.6	198
4	Diabetes and branched-chain amino acids: what is the link?. Journal of Diabetes, 2018, 10, 350-352.	1.8	153
5	Cohort profile: Risk evaluation of cancers in Chinese diabetic individuals: a longitudinal (REACTION) study	1.8	147
6	Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial). American Heart Journal, 2015, 170, 675-682.e8.	2.7	128
7	Iron-deficiency anemia, non-iron-deficiency anemia and HbA1c among adults in the US*. Journal of Diabetes, 2011, 3, 67-73.	1.8	119
8	Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Management of Dyslipidemia and Prevention of Cardiovascular Disease Algorithm " 2020 Executive Summary. Endocrine Practice, 2020, 26, 1196-1224.	2.1	117
9	Diabetes and COVID-19. Journal of Diabetes, 2020, 12, 347-348.	1.8	112
10	Predictive Value of Fasting Glucose, Postload Glucose, and Hemoglobin A1c on Risk of Diabetes and Complications in Chinese Adults. Diabetes Care, 2019, 42, 1539-1548.	8.6	102
11	Inflammation and Insulin Resistance. Diabetes Care, 2003, 26, 1922-1926.	8.6	74
12	Ideal Cardiovascular Health Metrics and Major Cardiovascular Events in Patients With Prediabetes and Diabetes. JAMA Cardiology, 2019, 4, 874.	6.1	70
13	American Association of Clinical Endocrinologists (AACE) Consensus Conference on the Insulin Resistance Syndrome. Diabetes Care, 2003, 26, 1297-1303.	8.6	66
14	Prognostic Significance of Long-term HbA1c Variability for All-Cause Mortality in the ACCORD Trial. Diabetes Care, 2020, 43, 1185-1190.	8.6	66
15	Diabetes Complications. Diabetes Care, 2004, 27, 1506-1514.	8.6	59
16	Screening for and managing diabetic retinopathy: Current approaches. American Journal of Health-System Pharmacy, 2007, 64, S8-S14.	1.0	55
17	A1C: Recommendations, Debates, and Questions. Diabetes Care, 2009, 32, e141-e147.	8.6	55
18	Obesity, Hypertension, and Insulin Resistance. Diabetes Care, 2002, 25, 2088-2097.	8.6	53

#	ARTICLE	IF	CITATIONS
19	Inflammation, Atherosclerosis, and Aspects of Insulin Action. <i>Diabetes Care</i> , 2005, 28, 2312-2319.	8.6	51
20	Insulin Resistance, Dyslipidemia, and Cardiovascular Disease. <i>Diabetes Care</i> , 2007, 30, 2164-2170.	8.6	50
21	The Jiangnan diet, a healthy diet pattern for Chinese. <i>Journal of Diabetes</i> , 2020, 12, 365-371.	1.8	50
22	Inflammation and Insulin Resistance. <i>Diabetes Care</i> , 2003, 26, 1619-1623.	8.6	46
23	Determinants of adherence to diabetes treatment. <i>Journal of Diabetes</i> , 2015, 7, 864-871.	1.8	46
24	Measures of Insulin Sensitivity. <i>Clinics in Laboratory Medicine</i> , 2006, 26, 611-633.	1.4	45
25	Second World Congress on the Insulin Resistance Syndrome: Insulin resistance syndrome and nonalcoholic fatty liver disease. <i>Diabetes Care</i> , 2005, 28, 1518-1523.	8.6	41
26	The kidney and cardiovascular outcome trials. <i>Journal of Diabetes</i> , 2018, 10, 88-89.	1.8	37
27	Diabetic Nephropathy. <i>Diabetes Care</i> , 2005, 28, 745-751.	8.6	36
28	Early Life Famine Exposure, Ideal Cardiovascular Health Metrics, and Risk of Incident Diabetes: Findings From the 4C Study. <i>Diabetes Care</i> , 2020, 43, 1902-1909.	8.6	36
29	Insulin Resistance Concepts. <i>Diabetes Care</i> , 2007, 30, 1320-1326.	8.6	34
30	Metabolic memory: Evolving concepts. <i>Journal of Diabetes</i> , 2018, 10, 186-187.	1.8	34
31	Thiazolidinediones. <i>Diabetes Care</i> , 2005, 28, 488-493.	8.6	30
32	Diabetes and cancer: Findings from the REACTION study. <i>Journal of Diabetes</i> , 2015, 7, 143-144.	1.8	30
33	The Avandia Debate. <i>Diabetes Care</i> , 2007, 30, 2401-2408.	8.6	29
34	Prevention of Obesity and Diabetes. <i>Diabetes Care</i> , 2003, 26, 3172-3178.	8.6	26
35	Diabetes in China: Prevalence, diagnosis, and control. <i>Journal of Diabetes</i> , 2015, 7, 143-144.	1.8	30
36	Dyslipidemia and the Metabolic Syndrome. <i>Diabetes Care</i> , 2004, 27, 3009-3016.	8.6	25

#	ARTICLE	IF	CITATIONS
37	Adiposity and Diabetes. <i>Diabetes Care</i> , 2002, 25, 2342-2349.	8.6	24
38	DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108101.	2.3	23
39	Cardiovascular Disease in Diabetes. <i>Diabetes Care</i> , 2010, 33, e49-e54.	8.6	22
40	Diabetic Retinopathy and Neuropathy. <i>Diabetes Care</i> , 2005, 28, 963-970.	8.6	21
41	Exploring Treatment Strategies for Type 2 Diabetes. <i>Diabetes Care</i> , 2007, 30, 2737-2745.	8.6	21
42	Diabetes and aging (ç³-â°¿ç—...ä,žè€é¾4,,â€-). <i>Journal of Diabetes</i> , 2013, 5, 369-371.	1.8	21
43	Consequences of Diabetes: Cardiovascular disease. <i>Diabetes Care</i> , 2004, 27, 1825-1831.	8.6	20
44	Diabetic Nephropathy. <i>Diabetes Care</i> , 2008, 31, 823-827.	8.6	19
45	How does CKD affect HbA1c?. <i>Journal of Diabetes</i> , 2018, 10, 270-270.	1.8	18
46	Clinical Diabetic Neuropathy. <i>Diabetes Care</i> , 2005, 28, 2968-2974.	8.6	17
47	Diabetic Retinopathy and Diabetic Neuropathy. <i>Diabetes Care</i> , 2007, 30, 760-765.	8.6	17
48	Diabetes and cancer relationships (ç³-â°¿ç—...ä,žè,¿ç~çš,,â...³è*æ€\$). <i>Journal of Diabetes</i> , 2013, 5, 378-390.	1.8	17
49	Diabetes during the COVID â€19 pandemic: A global call to reconnect with patients and emphasize lifestyle changes and optimize glycemic and blood pressure control. <i>Journal of Diabetes</i> , 2020, 12, 556-557.	1.8	16
50	The risk of sudden cardiac arrest and ventricular arrhythmia with rosiglitazone versus pioglitazone: real-world evidence on thiazolidinedione safety. <i>Cardiovascular Diabetology</i> , 2020, 19, 25.	6.8	16
51	Diabetes and stroke: An important complication. <i>Journal of Diabetes</i> , 2021, 13, 184-190.	1.8	16
52	Diabetic Neuropathy. <i>Diabetes Care</i> , 2007, 30, 1027-1032.	8.6	15
53	Approaches to treatment 2: Comparison of American Association of Clinical Endocrinologists (AACE) and American Diabetes Association (ADA) type 2 diabetes treatment guidelines. <i>Journal of Diabetes</i> , 2016, 8, 4-6.	1.8	15
54	What role will 'gliptins' play in glycemic control?. <i>Cleveland Clinic Journal of Medicine</i> , 2008, 75, 305-310.	1.3	15

#	ARTICLE	IF	CITATIONS
55	Treatment Issues in Type 1 Diabetes. <i>Diabetes Care</i> , 2002, 25, 230-238.	8.6	14
56	Insulin Resistance: Causes and Consequences. <i>International Review of Neurobiology</i> , 2005, 65, 1-24.	2.0	13
57	Approaches to Treatment of Pre-Diabetes and Obesity and Promising New Approaches to Type 2 Diabetes. <i>Diabetes Care</i> , 2008, 31, 1461-1466.	8.6	13
58	Is HbA1c < 7% a Marker of Poor Performance in Individuals > 65 Years Old?. <i>Diabetes Care</i> , 2017, 40, 526-528.	8.6	12
59	Fear of hypoglycemia. <i>Journal of Diabetes</i> , 2017, 9, 108-110.	1.8	12
60	American Society of Clinical Oncology Summit on Addressing Obesity Through Multidisciplinary Provider Collaboration: Key Findings and Recommendations for Action. <i>Obesity</i> , 2017, 25, S34-S39.	3.0	12
61	Journal of Diabetes: Ushering in Volume 10. <i>Journal of Diabetes</i> , 2018, 10, 4-5.	1.8	12
62	Achieving Glycemic Goals in Type 2 Diabetes. <i>Diabetes Care</i> , 2007, 30, 174-180.	8.6	11
63	Sodium glucose transporter 2 inhibition: A new approach to diabetes treatment (α -glucosidase inhibitors). <i>Diabetes</i> , 2013, 5, 225-227.	1.8	11
64	Approaches to Cardiovascular Disease and Its Treatment. <i>Diabetes Care</i> , 2003, 26, 3342-3348.	8.6	10
65	Concepts of Insulin Resistance. <i>Metabolic Syndrome and Related Disorders</i> , 2005, 3, 284-293.	1.3	10
66	Incretin Concepts. <i>Diabetes Care</i> , 2010, 33, e20-e25.	8.6	10
67	Five Ms of adherence. <i>Journal of Diabetes</i> , 2011, 3, 169-171.	1.8	10
68	Questioning glucose measurements used in the International Diabetes Federation (IDF) Atlas. <i>Journal of Diabetes</i> , 2016, 8, 746-747.	1.8	10
69	Glycemic Treatment: Control of glycemia. <i>Diabetes Care</i> , 2004, 27, 1227-1234.	8.6	9
70	Inpatient Diabetes Control: Approaches to treatment. <i>Diabetes Care</i> , 2004, 27, 2272-2277.	8.6	9
71	Cardiovascular Disease, Neuropathy, and Retinopathy. <i>Diabetes Care</i> , 2009, 32, e64-e68.	8.6	9
72	Discordance between HbA1c and glycemia. <i>Journal of Diabetes</i> , 2018, 10, 908-910.	1.8	9

#	ARTICLE	IF	CITATIONS
73	2nd International Symposium on Triglycerides and HDL: Metabolic syndrome. Diabetes Care, 2005, 28, 2577-2584.	8.6	8
74	Sodium-glucose cotransporter 2 inhibitors and diabetic ketoacidosis. Journal of Diabetes, 2016, 8, 175-176.	1.8	8
75	Temporal trends in ischemic stroke and anticoagulation therapy for non-valvular atrial fibrillation: effect of diabetes. Journal of Diabetes, 2017, 9, 115-122.	1.8	8
76	Fournier's gangrene and sodium-glucose cotransporter 2 inhibitors: Is there a causal association?. Journal of Diabetes, 2019, 11, 340-341.	1.8	8
77	Diabetes Issues in Women and Children: Polycystic ovary syndrome. Diabetes Care, 2003, 26, 2457-2463.	8.6	7
78	Inpatient Diabetes Control: Rationale. Diabetes Care, 2004, 27, 2074-2080.	8.6	7
79	Diabetes and Obesity. Diabetes Care, 2007, 30, 3145-3151.	8.6	7
80	Diabetes Treatment. Diabetes Care, 2009, 32, e25-e30.	8.6	7
81	Blood Pressure and Diabetic Nephropathy. Diabetes Care, 2010, 33, e30-e35.	8.6	7
82	Diabetes and tuberculosis: An important relationship. Journal of Diabetes, 2017, 9, 640-643.	1.8	7
83	Type 1 Diabetes and Glucose Monitoring. Diabetes Care, 2007, 30, 2965-2971.	8.6	6
84	World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease. Diabetes Care, 2011, 34, e152-e157.	8.6	6
85	Current Issues in Glp-1 Receptor Agonist Therapy for Type 2 Diabetes. Endocrine Practice, 2013, 18, 6-26.	2.1	6
86	Sodium-glucose cotransporter 2 inhibitors and renal function. Journal of Diabetes, 2016, 8, 175-176.	1.8	6
87	Is insulin the preferred treatment for HbA1c >9%?. Journal of Diabetes, 2017, 9, 814-816.	1.8	6
88	American College of Physicians diabetes guidelines attempt to turn back the clock, conflating good HbA1c with hypoglycemia. Journal of Diabetes, 2018, 10, 618-620.	1.8	6
89	Does glycemic control affect outcome of COVID-19?. Journal of Diabetes, 2020, 12, 868-869.	1.8	6
90	Developments in Diabetes and Insulin Resistance. Diabetes Care, 2006, 29, 161-167.	8.6	6

#	ARTICLE	IF	CITATIONS
91	Neuropathy, Womens' Health, and Socioeconomic Aspects of Diabetes. <i>Diabetes Care</i> , 2002, 25, 1085-1094.	8.6	5
92	Fat Metabolism and Diabetes: 2003 American Diabetes Association Postgraduate Course. <i>Diabetes Care</i> , 2003, 26, 2198-2203.	8.6	5
93	Aspects of Blood Pressure, Lipid, and Glycemic Treatment. <i>Diabetes Care</i> , 2004, 27, 264-269.	8.6	5
94	Gut Hormones, Obesity, Polycystic Ovarian Syndrome, Malignancy, and Lipodystrophy Syndromes. <i>Diabetes Care</i> , 2007, 30, 1934-1939.	8.6	5
95	World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease. <i>Diabetes Care</i> , 2011, 34, e126-e131.	8.6	5
96	Diabetes treatment: The coming paradigm shift. <i>Journal of Diabetes</i> , 2012, 4, 315-317.	1.8	5
97	ACE/ACE Position Statement on the use of follow-on Biologics and Biosimilars for Endocrine Diseases. <i>Endocrine Practice</i> , 2017, 23, 1345-1349.	2.1	5
98	Is the type of diabetes treatment relevant to outcome of COVID-19?. <i>Journal of Diabetes</i> , 2020, 12, 486-487.	1.8	5
99	Treatment Issues in Type 2 Diabetes. <i>Diabetes Care</i> , 2002, 25, 614-619.	8.6	4
100	Glycemic Treatment in Type 1 and Type 2 Diabetes. <i>Diabetes Care</i> , 2006, 29, 2549-2555.	8.6	4
101	Weight Control in Individuals With Diabetes. <i>Diabetes Care</i> , 2006, 29, 2749-2754.	8.6	4
102	Troubling ethical questions from gestational diabetes trial. <i>Journal of Diabetes</i> , 2010, 2, 1-4.	1.8	4
103	Fibrate use in diabetes: New concepts. <i>Journal of Diabetes</i> , 2011, 3, 1-2.	1.8	4
104	World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease. <i>Diabetes Care</i> , 2011, 34, e140-e145.	8.6	4
105	Helping people with diabetes to exercise. <i>Journal of Diabetes</i> , 2015, 7, 150-152.	1.8	4
106	Self-monitoring of blood glucose for type 2 diabetes. <i>Journal of Diabetes</i> , 2015, 7, 593-594.	1.8	4
107	Non-Alcoholic Fatty Liver Disease and Malignancy as Complications of Insulin Resistance. <i>Metabolic Syndrome and Related Disorders</i> , 2005, 3, 316-327.	1.3	3
108	Prevention of Cardiovascular Disease. <i>Diabetes Care</i> , 2007, 30, 423-431.	8.6	3

#	ARTICLE	IF	CITATIONS
127	Non-alcoholic fatty liver disease and type 2 diabetes: Importance of glycemic control. Journal of Diabetes, 2017, 9, 722-723.	1.8	2
128	Dipeptidyl peptidase-4 inhibitor approaches. Journal of Diabetes, 2017, 9, 5-7.	1.8	2
129	World congress on insulin resistance, diabetes and cardiovascular disease. Journal of Diabetes, 2018, 10, 776-777.	1.8	2
130	Evolution of type 2 diabetes mellitus treatment approaches. Journal of Diabetes, 2019, 11, 4-6.	1.8	2
131	Lipids as risk markers for type 2 diabetes. Journal of Diabetes, 2019, 11, 176-178.	1.8	2
132	Management and prevention of cardiovascular disease for type 2 diabetes: Integrating the diabetes management recommendations of AACE, ADA, EASD, AHA, ACC, and ESC. American Journal of Preventive Cardiology, 2020, 1, 100007.	3.0	2
133	Developments in type 1 and type 2 diabetes. Journal of Diabetes, 2021, 13, 530-531.	1.8	2
134	Approaching Treatment of the Insulin Resistance Syndrome. Metabolic Syndrome and Related Disorders, 2005, 3, 328-331.	1.3	1
135	Insulin Resistance in Children and in the Polycystic Ovarian Syndrome. Metabolic Syndrome and Related Disorders, 2005, 3, 294-304.	1.3	1
136	Does a structured patient education program improve glycemic control in individuals with type 2 diabetes mellitus?. Nature Clinical Practice Endocrinology and Metabolism, 2007, 3, 390-391.	2.8	1
137	Topics in Type 2 Diabetes and Insulin Resistance. Diabetes Care, 2009, 32, e13-e19.	8.6	1
138	Recent cardiovascular trials: What are the drivers of benefit and adverse effect?. Journal of Diabetes, 2009, 1, 227-229.	1.8	1
139	Learning from ORIGIN. Journal of Diabetes, 2012, 4, 191-192.	1.8	1
140	Sugar-sweetened beverages: Changing the tide (â€œâ€). Journal of Diabetes, 2013, 5, 1-2.	1.8	1
141	Approaches to treatment 1: How is type 2 diabetes actually treated?. Journal of Diabetes, 2015, 7, 747-748.	1.8	1
142	The Future of Diabetes. Canadian Journal of Diabetes, 2015, 39, 204-205.	0.8	1
143	Metformin and renal insufficiencyâ€”is 45, or even 30, the new 60?. Nature Reviews Endocrinology, 2015, 11, 693-694.	9.6	1
144	New approaches to wound healing for diabetes. Journal of Diabetes, 2015, 7, 435-436.	1.8	1

#	ARTICLE	IF	CITATIONS
145	Concomitant Diabetes and Atrial Fibrillation. Journal of the American College of Cardiology, 2017, 70, 1336-1338.	2.8	1
146	Talks and tweets from the ADA. Journal of Diabetes, 2018, 10, 812-815.	1.8	1
147	Adherence and diabetes. Journal of Diabetes, 2018, 10, 692-694.	1.8	1
148	Introduction to the 2nd Heart in Diabetes (HiD) Meeting. Journal of Diabetes, 2019, 11, 599-600.	1.8	1
149	Implications of the recent CVOTs in type 2 diabetes: The right place for DPP-IV inhibitors today. Diabetes Research and Clinical Practice, 2019, 157, 107906.	2.8	1
150	Acupuncture for painful diabetic neuropathy. Journal of Diabetes, 2019, 11, 924-924.	1.8	1
151	Diabetes phenotypes: Beyond IDDM vs NIDDM. Journal of Diabetes, 2019, 11, 698-699.	1.8	1
152	Glucokinase and the potential of glucokinase activation in type 2 diabetes. Journal of Diabetes, 2019, 11, 626-627.	1.8	1
153	Insulin resistance: looking back, looking forward. Journal of Diabetes, 2020, 12, 184-186.	1.8	1
154	COVID-19 in the United States: Where are we now? Where have we been?. Journal of Diabetes, 2021, 13, 98-100.	1.8	1
155	Rationale for glycemic control to improve cardiovascular outcome: Lessons from east and west. Journal of Diabetes, 2021, 13, 698-700.	1.8	1
156	Biosimilar insulin concepts. Journal of Diabetes, 2022, 14, 231-235.	1.8	1
157	The 2022 American Diabetes Association Meeting. Journal of Diabetes, 0, , .	1.8	1
158	Type 1 Diabetes and Hypoglycemia. Diabetes Care, 2009, 32, e1-e4.	8.6	0
159	Nephropathy and Other Topics. Diabetes Care, 2009, 32, e94-e98.	8.6	0
160	Diabetes in youth: A dilemma of pathogenesis. Journal of Diabetes, 2011, 3, 91-92.	1.8	0
161	Metformin associated with better cardiovascular outcomes than other glycaemic therapies. Evidence-Based Medicine, 2014, 19, 103-103.	0.6	0
162	Role of glucagon in treating diabetes: Evidence and concepts (èf°é«~è €ç³-ç`âœ`ç³-â°¿ç—...æ²»ç—-ä,çš,,äl/2œç”1/4šë-ee@äZæ ,â¿µ).		

#	ARTICLE	IF	CITATIONS
163	Advances in sleep research çıçœçş,,ç”ç©¶è¿>â±•. Journal of Diabetes, 2015, 7, 8-9.	1.8	0
164	Treatment: Concepts and new developments. Journal of Diabetes, 2016, 8, 297-299.	1.8	0
165	Chelation for diabetes complications: <sc>A</sc> neglected approach?. Journal of Diabetes, 2017, 9, 318-319.	1.8	0
166	Diabetes treatment over age 65: <sc>I</sc>s worse control really better?. Journal of Diabetes, 2017, 9, 428-430.	1.8	0
167	Upper extremity arthropathy in diabetes. Journal of Diabetes, 2017, 9, 542-543.	1.8	0
168	What strategies are implied by STRATEGY?. Science China Life Sciences, 2017, 60, 319-320.	4.9	0
169	The <i>Journal of Diabetes</i> in its ninth year. Journal of Diabetes, 2017, 9, 214-214.	1.8	0
170	Response to Comment on Bloomgarden et al. Is HbA1c <7% a Marker of Poor Performance in Individuals >65 Years Old? Diabetes Care 2017;40:526â€“528. Diabetes Care, 2017, 40, e154-e154.	8.6	0
171	Transition from hospital to outpatient diabetes care. Journal of Diabetes, 2018, 10, 538-540.	1.8	0
172	The heart in diabetes meeting. Journal of Diabetes, 2019, 11, 840-841.	1.8	0
173	ADA2019. Journal of Diabetes, 2019, 11, 778-780.	1.8	0
174	What constitutes good research?. Journal of Diabetes, 2019, 11, 502-504.	1.8	0
175	Notes from the world congress on insulin resistance, diabetes, and cardiovascular disease. Journal of Diabetes, 2019, 11, 258-260.	1.8	0
176	Supplements. Journal of Diabetes, 2019, 11, 100-101.	1.8	0
177	Sodiumâ€“glucose cotransporter 2 inhibitors for macroalbuminuria: A new indication. Journal of Diabetes, 2020, 12, 8-9.	1.8	0
178	The ADA 2020 virtual poster hall. Journal of Diabetes, 2020, 12, 778-780.	1.8	0
179	New insights into the older hypoglycemic agents in type 2 diabetes therapy. Journal of Diabetes, 2020, 12, 844-847.	1.8	0
180	Tweeting, tweeting. Journal of Diabetes, 2020, 12, 424-425.	1.8	0

#	ARTICLE	IF	CITATIONS
181	Which person with diabetes should receive cardioprotective glucose-lowering medicines?. Journal of Diabetes, 2020, 12, 352-353.	1.8	0
182	Paradigm shift in the management of <scp>DM</scp> & <scp>CVD</scp>â€”preventing the next <scp>CV</scp> event. Journal of Diabetes, 2020, 12, 630-632.	1.8	0
183	Andrew Jay Drexler, in memoriam. Journal of Diabetes, 2020, 12, 712-713.	1.8	0
184	Use of online information in diabetes. Journal of Diabetes, 2020, 12, 268-269.	1.8	0
185	Various and sundry recent publications. Journal of Diabetes, 2021, 13, 4-6.	1.8	0
186	Use of <scp>HbA1c</scp> in clinical practice: New insights. Journal of Diabetes, 2021, 13, 280-281.	1.8	0
187	Glycemic treatment: Further concepts. Journal of Diabetes, 2021, 13, 362-363.	1.8	0
188	Celiac disease: A global survey. Journal of Diabetes, 2021, 13, 446-447.	1.8	0
189	Type 2 diabetes in the young in South Asia: Clinical heterogeneity and need for aggressive public health measures. Journal of Diabetes, 2021, 13, 610-612.	1.8	0
190	Presentations at the 81st scientific sessions of the <scp>American Diabetes Association</scp> (<scp>ADA</scp>), Part 1. Journal of Diabetes, 2021, 13, 768-769.	1.8	0
191	Presentations at the 81st scientific sessions of the American Diabetes Association , part 2. Journal of Diabetes, 2021, 13, 844-846.	1.8	0
192	The journal of diabetes is adopting open access. Journal of Diabetes, 2021, , .	1.8	0
193	The Fifth Annual Heart in Diabetes Conference (Part 1). Journal of Diabetes, 2021, 13, 946-948.	1.8	0
194	The 5 th Annual Heart in Diabetes Conference (part 2). Journal of Diabetes, 2022, 14, 93-96.	1.8	0
195	The world congress on insulin resistance, diabetes, and cardiovascular disease (<scp>WCIRDC</scp>) Tj ETQq1 1 0.784314 ggBT /Overl	1.8	0
196	Cardiovascular Disease. Diabetes Care, 2006, 29, 1160-1166.	8.6	0
197	Learning by reading: A review of recent diabetes articles. Journal of Diabetes, 2022, 14, 301-305.	1.8	0
198	The Chinese Metabolic Management Centers. Journal of Diabetes, 2022, 14, 362-364.	1.8	0